

Electroceuticals: Technologies and Global Markets

Market Research Report | 2022-06-30 | 117 pages | BCC Research

AVAILABLE LICENSES:

- Single User License \$5500.00
- 2-5 Users License \$6600.00
- Site License \$7920.00
- Enterprise License \$9504.00

Report description:

Description

Report Scope:

This report highlights the current and future market potential for electroceuticals. It provides a detailed analysis of the competitive environment, regulatory scenario, and the drivers, restraints, opportunities, and trends in the market. The report also offers market projections through 2027.

This report covers the overall electroceuticals market, including cardiac pacemakers, implantable cardiac defibrillators, hearing aids and implants, and neurostimulation devices. The report also analyzes various end users of electroceuticals.

For this report, the market has been segmented into North America, Europe, Asia-Pacific and the Rest of the World (RoW), which includes Latin America, the Middle East and Africa). Major countries, including the U.S., Canada, Germany, the U.K., France, Spain, Italy, Japan, China and India) are analyzed. Market data was provided for 2020, which served as the base year, and forecasts are estimated through 2027. Estimated values are based on product manufacturers' total revenues. Projected and forecast revenue values are in constant U.S. dollars that have not been adjusted for inflation.

Report Includes:

- 19 data tables and 24 additional tables
- An overview of global markets and technologies for electroceuticals
- Analyses of global market trends, with data from 2021, estimates for 2022, and projections of compound annual growth rates (CAGRs) through 2027
- Discussion on how electroceuticals are used as an alternative to drug-based remedies and analyses of endogenous and

Scotts International. EU Vat number: PL 6772247784

exogenous factors that are impacting the global market growth

- Coverage of several diseases such as epilepsy, cardiovascular diseases, rheumatoid arthritis and diabetes and their treatment using electroceuticals
- Information on RecoveryRx medical device, which is used for the treatment of postoperative pain of opioid/NSAID therapy
- Coverage of regulatory landscape, product recalls, pipeline products, and discussion on future perspective, strategies, and developments of the industry
- Identification of market drivers, restraints and other forces impacting the global market and evaluation of current market trends, market size, and forecast
- Market share analysis of the key companies of the industry and coverage of events like mergers & acquisitions, joint ventures, collaborations or partnerships, and other key market strategies and a relevant patent analysis
- Company profiles of major players Abbott Laboratories, Boston Scientific, GlaxoSmithKline plc, Medtronic plc, Edwards Lifesciences Corp.

Executive Summary

Summary:

The global electroceuticals market was valued at \$REDACTED in 2020 and is expected to be valued at \$REDACTED by the end of 2027, at a CAGR of REDACTED%. The market's growth is mainly attributed to the increasing incidence of neurological disorders and cardiac diseases.

Electroceuticals are medical devices that are used to restore health in patients. Patients can hold these devices against the skin, or they can be implanted. These devices, also known as bioelectric medicine, represent an alternative to drug-based remedies. They are usually not the first line of treatment, and tend to be used only when health cannot be restored with drugs. Most electroceuticals do not cure conditions, but can reduce pain and avoid affected parts of the body. Electroceuticals function through neurostimulation and modulation of the nervous system through electrical impulses. Electroceutical devices are used to treat several ailments and disorders related to neurology and cardiology through invasive and non-invasive methods.

The human nervous system works as the commander of the human body, and, as such, plays a major role in treating disorders of the body. Neurostimulation technology involves the alteration or modulation of nerves. Neurostimulation devices directly deliver electrical current or magnetic impulses to nerves to modify their activities.

Over the last 30 years, neurostimulation has emerged as one of the most dynamic and exciting therapy fields, and has been investigated for the treatment of a range of clinical conditions, including chronic pain, movement disorders (Parkinson's disease, tremor, dystonia and others), epilepsy (which affects 50 million people worldwide), functional restoration, and psychiatric, cardiovascular, gastrointestinal and genitourinary disorders. The potential of neurostimulation technology is being explored in several other clinical conditions, including obesity, tinnitus and central nervous system disorders.

Table of Contents:

Table of Contents
Chapter 1 Introduction
Study Goals and Objectives
Reasons for Doing this Study
What's New in this Update?
Scope of Report
Information Sources
Methodology

Scotts International. EU Vat number: PL 6772247784

Geographic Breakdown

Analyst's Credentials

BCC Custom Research

Related BCC Research Reports

Chapter 2 Executive Summary

Chapter 3 Overview

Introduction

Neurostimulation

Cardioverter Defibrillators and Cardiac Pacemakers

Public Access Defibrillators

Battery Technology for Implantable Cardiac Defibrillators

Regulatory Framework

United States

European Union

Japan

Chapter 4 Market Dynamics

Market Drivers

Increasing Incidence of CVD, Neurology and ENT Disorders

Aging Population

Increasing Healthcare Expenditures

Focus on Non-drug Therapies and Reducing Opioid Usage

Technology Innovations and New Product Developments

Market Restraints and Challenges

High Cost of Neurostimulation Procedures/Devices and Lack of Trained Healthcare Professionals

Inconsistent Reimbursement Policies

Chapter 5 Impact of COVID-19 Pandemic

Introduction

Impact on Neurostimulation Market

Impact on Market for ENT Devices

Chapter 6 Global Market for Electroceuticals by Product

Cardioverter Defibrillators and Cardiac Pacemakers

Neurostimulation

Spinal Cord Stimulation

Deep Brain Stimulation

Vagus Nerve Stimulation

Sacral Nerve Stimulation

Transcutaneous Electrical Nerve Stimulation

Other Stimulators

Hearing Aids and Implants

Hearing Aid Devices

Behind the Ear

Completely in the Canal

In the Ear

Hearing Implants

Cochlear Implants

Bone Anchored Hearing Implants

Middle Ear Implants

Scotts International, EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Chapter 7 Global Market for Electroceuticals by End User

Hospitals and Clinics

Homecare and Others

Chapter 8 Global Market for Electroceuticals by Region

North America

U.S.

Europe

Asia-Pacific

Japan

China

India

Rest of the World

Chapter 9 Patent Review

Introduction

Patents on Hearing Aids and Implants

Neurostimulation

Cardiac

Chapter 10 Competitive Landscape

Leading Companies in the Market for Neurostimulation Products

Spinal Cord Stimulation Devices

Deep Brain Stimulation Devices

Market for Hearing Aids and Implants by Company

Key Developments

Chapter 11 Company Profiles

ABBOTT LABORATORIES

AXONICS MODULATION TECHNOLOGIES INC.

BIOVENTUS LLC

BIOTRONIK SE & CO. KG

BOSTON SCIENTIFIC CORP.

COCHLEAR AMERICAS

COOK MEDICAL

EDWARDS LIFESCIENCES CORP.

GLAXOSMITHKLINE PLC

LEPU MEDICAL TECHNOLOGY (BEIJING) CO. LTD.

LIVANOVA PLC

MEDICO S.P.A.

MEDTRONIC PLC

MICROPORT SCIENTIFIC CORP.

STRYKER CORP.

ZOLL MEDICAL CORP.

Chapter 12 Appendix: Acronyms

Scotts International. EU Vat number: PL 6772247784



To place an Order with Scotts International:

Electroceuticals: Technologies and Global Markets

Market Research Report | 2022-06-30 | 117 pages | BCC Research

- Print this form				
Complete the rele	vant blank fields and sign			
☐ - Send as a scanned	d email to support@scotts-internat	tional.com		
ORDER FORM:				
Select license	License			Price
	Single User License			\$5500.00
	2-5 Users License			\$6600.00
	Site License			\$7920.00
	Enterprise License			\$9504.00
			VAT	
			Total	
*Diagonal diagonal di	liana akina Fanananakina ak			04.246
	: license option. For any questions plea 3% for Polish based companies, individ			
vAT will be added at 2	.5% for Polish based companies, individ	duais and EO based Con	ipanies who are unable to provide a	valid EU vat Nullibers
Email*		Phone*		
First Name*		Last Name*		
Job title*				
Company Name*		EU Vat / Tax ID / NI	P number*	\neg
Address*		City*		
Zip Code*		Country*		
		Date	2025-05-04	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com www.scotts-international.com

Signature

Scotts International. EU Vat number: PL 6772247784